Zhongchao Inc. (ZCMD) Stock Competitors & Peer Comparison

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, VEEV has a market cap of 29.9B. Regarding current trading prices, ZCMD is priced at $1.12, while VEEV trades at $184.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas VEEV's P/E ratio is 22.12. In terms of profitability, ZCMD's ROE is -0.32%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, ZCMD is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check VEEV's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, GEHC has a market cap of 29.5B. Regarding current trading prices, ZCMD is priced at $1.12, while GEHC trades at $64.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas GEHC's P/E ratio is 14.22. In terms of profitability, ZCMD's ROE is -0.32%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ZCMD is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check GEHC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, ZCMD is priced at $1.12, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas GEHCV's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, ZCMD is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check GEHCV's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, BTSGU has a market cap of 13.8B. Regarding current trading prices, ZCMD is priced at $1.12, while BTSGU trades at $229.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas BTSGU's P/E ratio is 208.78. In terms of profitability, ZCMD's ROE is -0.32%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BTSGU's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, BTSG has a market cap of 13.7B. Regarding current trading prices, ZCMD is priced at $1.12, while BTSG trades at $69.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas BTSG's P/E ratio is 56.33. In terms of profitability, ZCMD's ROE is -0.32%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BTSG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, TEM has a market cap of 10.8B. Regarding current trading prices, ZCMD is priced at $1.12, while TEM trades at $61.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas TEM's P/E ratio is -123.20. In terms of profitability, ZCMD's ROE is -0.32%, compared to TEM's ROE of -0.70%. Regarding short-term risk, ZCMD is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TEM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, ZCMD is priced at $1.12, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SGFY's P/E ratio is 70.91. In terms of profitability, ZCMD's ROE is -0.32%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, ZCMD is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SGFY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, HQY has a market cap of 7.7B. Regarding current trading prices, ZCMD is priced at $1.12, while HQY trades at $92.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas HQY's P/E ratio is 21.56. In terms of profitability, ZCMD's ROE is -0.32%, compared to HQY's ROE of +0.11%. Regarding short-term risk, ZCMD is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HQY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, HNGE has a market cap of 6.6B. Regarding current trading prices, ZCMD is priced at $1.12, while HNGE trades at $85.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas HNGE's P/E ratio is 43.66. In terms of profitability, ZCMD's ROE is -0.32%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, ZCMD is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HNGE's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, RCM has a market cap of 6B. Regarding current trading prices, ZCMD is priced at $1.12, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas RCM's P/E ratio is -102.21. In terms of profitability, ZCMD's ROE is -0.32%, compared to RCM's ROE of +0.00%. Regarding short-term risk, ZCMD is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check RCM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, TXG has a market cap of 5B. Regarding current trading prices, ZCMD is priced at $1.12, while TXG trades at $39.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas TXG's P/E ratio is -229.71. In terms of profitability, ZCMD's ROE is -0.32%, compared to TXG's ROE of -0.03%. Regarding short-term risk, ZCMD is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TXG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, DOCS has a market cap of 4B. Regarding current trading prices, ZCMD is priced at $1.12, while DOCS trades at $21.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas DOCS's P/E ratio is 14.11. In terms of profitability, ZCMD's ROE is -0.32%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, ZCMD is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check DOCS's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, ZCMD is priced at $1.12, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas ONEM's P/E ratio is -7.77. In terms of profitability, ZCMD's ROE is -0.32%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, ZCMD is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ONEM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, PRVA has a market cap of 3.4B. Regarding current trading prices, ZCMD is priced at $1.12, while PRVA trades at $26.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas PRVA's P/E ratio is 168.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, ZCMD is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PRVA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, HTFL has a market cap of 2.6B. Regarding current trading prices, ZCMD is priced at $1.12, while HTFL trades at $30.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas HTFL's P/E ratio is -15.28. In terms of profitability, ZCMD's ROE is -0.32%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, ZCMD is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HTFL's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, ZCMD is priced at $1.12, while PINC trades at $28.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas PINC's P/E ratio is 19.22. In terms of profitability, ZCMD's ROE is -0.32%, compared to PINC's ROE of -0.02%. Regarding short-term risk, ZCMD is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PINC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, PGNY has a market cap of 2.3B. Regarding current trading prices, ZCMD is priced at $1.12, while PGNY trades at $29.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas PGNY's P/E ratio is 21.50. In terms of profitability, ZCMD's ROE is -0.32%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, ZCMD is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PGNY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, ZCMD is priced at $1.12, while WGS trades at $71.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas WGS's P/E ratio is 84.36. In terms of profitability, ZCMD's ROE is -0.32%, compared to WGS's ROE of -0.28%. Regarding short-term risk, ZCMD is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check WGS's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, WGSWW has a market cap of 1.8B. Regarding current trading prices, ZCMD is priced at $1.12, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas WGSWW's P/E ratio is -0.09. In terms of profitability, ZCMD's ROE is -0.32%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, ZCMD is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check WGSWW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, TDOC has a market cap of 1.6B. Regarding current trading prices, ZCMD is priced at $1.12, while TDOC trades at $9.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas TDOC's P/E ratio is -10.11. In terms of profitability, ZCMD's ROE is -0.32%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, ZCMD is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TDOC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, ZCMD is priced at $1.12, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas NXGN's P/E ratio is -266.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, ZCMD is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check NXGN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, ZCMD is priced at $1.12, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas AGTI's P/E ratio is -71.79. In terms of profitability, ZCMD's ROE is -0.32%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, ZCMD is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AGTI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, OMDA has a market cap of 1.3B. Regarding current trading prices, ZCMD is priced at $1.12, while OMDA trades at $22.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas OMDA's P/E ratio is 323.14. In terms of profitability, ZCMD's ROE is -0.32%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, ZCMD is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check OMDA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, NUTX has a market cap of 1.1B. Regarding current trading prices, ZCMD is priced at $1.12, while NUTX trades at $190.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas NUTX's P/E ratio is 14.74. In terms of profitability, ZCMD's ROE is -0.32%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, ZCMD is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check NUTX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, GDRX has a market cap of 1.1B. Regarding current trading prices, ZCMD is priced at $1.12, while GDRX trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas GDRX's P/E ratio is 9.27. In terms of profitability, ZCMD's ROE is -0.32%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, ZCMD is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check GDRX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CERT has a market cap of 1B. Regarding current trading prices, ZCMD is priced at $1.12, while CERT trades at $6.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CERT's P/E ratio is 17.26. In terms of profitability, ZCMD's ROE is -0.32%, compared to CERT's ROE of -0.01%. Regarding short-term risk, ZCMD is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CERT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, ZCMD is priced at $1.12, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CCLDO's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CCLDO's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, HSTM has a market cap of 826.2M. Regarding current trading prices, ZCMD is priced at $1.12, while HSTM trades at $28.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas HSTM's P/E ratio is 37.21. In terms of profitability, ZCMD's ROE is -0.32%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, ZCMD is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HSTM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, PHR has a market cap of 663.2M. Regarding current trading prices, ZCMD is priced at $1.12, while PHR trades at $10.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas PHR's P/E ratio is 38.32. In terms of profitability, ZCMD's ROE is -0.32%, compared to PHR's ROE of +0.03%. Regarding short-term risk, ZCMD is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PHR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, EVH has a market cap of 645.1M. Regarding current trading prices, ZCMD is priced at $1.12, while EVH trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas EVH's P/E ratio is 573.50. In terms of profitability, ZCMD's ROE is -0.32%, compared to EVH's ROE of -0.78%. Regarding short-term risk, ZCMD is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check EVH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, ZCMD is priced at $1.12, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, ZCMD is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MPLN-WT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, ZCMD is priced at $1.12, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas ACCD's P/E ratio is -3.08. In terms of profitability, ZCMD's ROE is -0.32%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, ZCMD is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ACCD's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, ZCMD is priced at $1.12, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CCLDP's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CCLDP's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CTEV has a market cap of 552.4M. Regarding current trading prices, ZCMD is priced at $1.12, while CTEV trades at $32.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CTEV's P/E ratio is -2.49. In terms of profitability, ZCMD's ROE is -0.32%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, ZCMD is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CTEV's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, ZCMD is priced at $1.12, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SHCR's P/E ratio is -3.76. In terms of profitability, ZCMD's ROE is -0.32%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, ZCMD is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SHCR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, NRC has a market cap of 503.5M. Regarding current trading prices, ZCMD is priced at $1.12, while NRC trades at $22.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas NRC's P/E ratio is 25.39. In terms of profitability, ZCMD's ROE is -0.32%, compared to NRC's ROE of +0.57%. Regarding short-term risk, ZCMD is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check NRC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, ZCMD is priced at $1.12, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, ZCMD's ROE is -0.32%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, ZCMD is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check SLGCW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, ZCMD is priced at $1.12, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SLGC's P/E ratio is -3.04. In terms of profitability, ZCMD's ROE is -0.32%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, ZCMD is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check SLGC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, TBRG has a market cap of 393.4M. Regarding current trading prices, ZCMD is priced at $1.12, while TBRG trades at $26.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas TBRG's P/E ratio is 9.37. In terms of profitability, ZCMD's ROE is -0.32%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, ZCMD is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TBRG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SOPH has a market cap of 384.2M. Regarding current trading prices, ZCMD is priced at $1.12, while SOPH trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SOPH's P/E ratio is -10.75. In terms of profitability, ZCMD's ROE is -0.32%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, ZCMD is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SOPH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, ZCMD is priced at $1.12, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas MPLN's P/E ratio is -0.23. In terms of profitability, ZCMD's ROE is -0.32%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, ZCMD is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check MPLN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SLP has a market cap of 370.8M. Regarding current trading prices, ZCMD is priced at $1.12, while SLP trades at $18.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SLP's P/E ratio is 17.82. In terms of profitability, ZCMD's ROE is -0.32%, compared to SLP's ROE of -0.49%. Regarding short-term risk, ZCMD is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SLP's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, ZCMD is priced at $1.12, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas TRHC's P/E ratio is -4.27. In terms of profitability, ZCMD's ROE is -0.32%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, ZCMD is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TRHC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, ZCMD is priced at $1.12, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SMFR's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, ZCMD is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check SMFR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SY has a market cap of 223.1M. Regarding current trading prices, ZCMD is priced at $1.12, while SY trades at $1.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SY's P/E ratio is -5.15. In terms of profitability, ZCMD's ROE is -0.32%, compared to SY's ROE of -0.16%. Regarding short-term risk, ZCMD is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check SY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SPOK has a market cap of 220.8M. Regarding current trading prices, ZCMD is priced at $1.12, while SPOK trades at $10.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SPOK's P/E ratio is 17.62. In terms of profitability, ZCMD's ROE is -0.32%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, ZCMD is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SPOK's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, AMWL has a market cap of 157.1M. Regarding current trading prices, ZCMD is priced at $1.12, while AMWL trades at $9.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas AMWL's P/E ratio is -1.81. In terms of profitability, ZCMD's ROE is -0.32%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, ZCMD is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AMWL's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, HCAT has a market cap of 153M. Regarding current trading prices, ZCMD is priced at $1.12, while HCAT trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas HCAT's P/E ratio is 10.35. In terms of profitability, ZCMD's ROE is -0.32%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, ZCMD is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HCAT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, ZCMD is priced at $1.12, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CPSI's P/E ratio is -183.80. In terms of profitability, ZCMD's ROE is -0.32%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, ZCMD is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CPSI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, ZCMD is priced at $1.12, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas AUGX's P/E ratio is -4.99. In terms of profitability, ZCMD's ROE is -0.32%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, ZCMD is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AUGX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, OPRX has a market cap of 114.1M. Regarding current trading prices, ZCMD is priced at $1.12, while OPRX trades at $6.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas OPRX's P/E ratio is 5.58. In terms of profitability, ZCMD's ROE is -0.32%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, ZCMD is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check OPRX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CCLD has a market cap of 96.5M. Regarding current trading prices, ZCMD is priced at $1.12, while CCLD trades at $2.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CCLD's P/E ratio is 6.88. In terms of profitability, ZCMD's ROE is -0.32%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CCLD's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, DH has a market cap of 84.4M. Regarding current trading prices, ZCMD is priced at $1.12, while DH trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas DH's P/E ratio is 3.08. In terms of profitability, ZCMD's ROE is -0.32%, compared to DH's ROE of -0.67%. Regarding short-term risk, ZCMD is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check DH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, ZCMD is priced at $1.12, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas FORA's P/E ratio is -24.11. In terms of profitability, ZCMD's ROE is -0.32%, compared to FORA's ROE of -0.17%. Regarding short-term risk, ZCMD is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check FORA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, ONMD has a market cap of 39.7M. Regarding current trading prices, ZCMD is priced at $1.12, while ONMD trades at $0.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas ONMD's P/E ratio is -4.86. In terms of profitability, ZCMD's ROE is -0.32%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, ZCMD is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ONMD's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, ZCMD is priced at $1.12, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SNCE's P/E ratio is -0.27. In terms of profitability, ZCMD's ROE is -0.32%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, ZCMD is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SNCE's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, ZCMD is priced at $1.12, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas AKLI's P/E ratio is -0.71. In terms of profitability, ZCMD's ROE is -0.32%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, ZCMD is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AKLI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, ZCMD is priced at $1.12, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SHLT's P/E ratio is -3.87. In terms of profitability, ZCMD's ROE is -0.32%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, ZCMD is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SHLT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, ZCMD is priced at $1.12, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, ZCMD is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SHCRW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, ONMDW has a market cap of 31.4M. Regarding current trading prices, ZCMD is priced at $1.12, while ONMDW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas ONMDW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, ZCMD is more volatile compared to ONMDW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ONMDW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, EUDA has a market cap of 28M. Regarding current trading prices, ZCMD is priced at $1.12, while EUDA trades at $14.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas EUDA's P/E ratio is -2.75. In terms of profitability, ZCMD's ROE is -0.32%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, ZCMD is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check EUDA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, ZCMD is priced at $1.12, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas STRM's P/E ratio is -2.40. In terms of profitability, ZCMD's ROE is -0.32%, compared to STRM's ROE of -0.32%. Regarding short-term risk, ZCMD is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check STRM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, ZCMD is priced at $1.12, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas RNLX's P/E ratio is -0.33. In terms of profitability, ZCMD's ROE is -0.32%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, ZCMD is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check RNLX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, ZCMD is priced at $1.12, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas LIFW's P/E ratio is -0.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, ZCMD is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check LIFW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, BEATW has a market cap of 20.4M. Regarding current trading prices, ZCMD is priced at $1.12, while BEATW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas BEATW's P/E ratio is -0.06. In terms of profitability, ZCMD's ROE is -0.32%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, ZCMD is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BEATW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, ZCMD is priced at $1.12, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas BBLN's P/E ratio is -0.04. In terms of profitability, ZCMD's ROE is -0.32%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, ZCMD is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BBLN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, ZCMD is priced at $1.12, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas ETAO's P/E ratio is -0.01. In terms of profitability, ZCMD's ROE is -0.32%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, ZCMD is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check ETAO's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, BFRG has a market cap of 8.3M. Regarding current trading prices, ZCMD is priced at $1.12, while BFRG trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas BFRG's P/E ratio is -1.31. In terms of profitability, ZCMD's ROE is -0.32%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, ZCMD is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BFRG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, ZCMD is priced at $1.12, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas HLTH's P/E ratio is -0.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, ZCMD is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check HLTH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, SCNX has a market cap of 5.5M. Regarding current trading prices, ZCMD is priced at $1.12, while SCNX trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas SCNX's P/E ratio is -0.14. In terms of profitability, ZCMD's ROE is -0.32%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, ZCMD is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SCNX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, ZCMD is priced at $1.12, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, ZCMD is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check UPH-WT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, ZCMD is priced at $1.12, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas UPH's P/E ratio is -0.07. In terms of profitability, ZCMD's ROE is -0.32%, compared to UPH's ROE of -1.05%. Regarding short-term risk, ZCMD is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check UPH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, MGRX has a market cap of 4.3M. Regarding current trading prices, ZCMD is priced at $1.12, while MGRX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas MGRX's P/E ratio is -0.31. In terms of profitability, ZCMD's ROE is -0.32%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, ZCMD is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check MGRX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, ZCMD is priced at $1.12, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas PEAR's P/E ratio is -0.08. In terms of profitability, ZCMD's ROE is -0.32%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, ZCMD is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check PEAR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, ZCMD is priced at $1.12, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas PEARW's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, ZCMD is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check PEARW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, ZCMD is priced at $1.12, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas OTRK's P/E ratio is -0.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, ZCMD is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check OTRK's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, HCTI has a market cap of 2.2M. Regarding current trading prices, ZCMD is priced at $1.12, while HCTI trades at $1.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas HCTI's P/E ratio is -0.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, ZCMD is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HCTI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, VSEE has a market cap of 1.9M. Regarding current trading prices, ZCMD is priced at $1.12, while VSEE trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas VSEE's P/E ratio is -0.22. In terms of profitability, ZCMD's ROE is -0.32%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, ZCMD is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check VSEE's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, ACON has a market cap of 1.6M. Regarding current trading prices, ZCMD is priced at $1.12, while ACON trades at $3.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas ACON's P/E ratio is -0.29. In terms of profitability, ZCMD's ROE is -0.32%, compared to ACON's ROE of -0.54%. Regarding short-term risk, ZCMD is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ACON's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, ZCMD is priced at $1.12, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CMAX's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, ZCMD is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CMAX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, BFRGW has a market cap of 1.5M. Regarding current trading prices, ZCMD is priced at $1.12, while BFRGW trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas BFRGW's P/E ratio is -1.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, ZCMD is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BFRGW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, VSEEW has a market cap of 1.5M. Regarding current trading prices, ZCMD is priced at $1.12, while VSEEW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas VSEEW's P/E ratio is -0.06. In terms of profitability, ZCMD's ROE is -0.32%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, ZCMD is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check VSEEW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, ZCMD is priced at $1.12, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, ZCMD is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check LIFWZ's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, EUDAW has a market cap of 1M. Regarding current trading prices, ZCMD is priced at $1.12, while EUDAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, ZCMD's ROE is -0.32%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, ZCMD is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check EUDAW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, ZCMD is priced at $1.12, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, ZCMD is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MSPRZ's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, ZCMD is priced at $1.12, while WORX trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas WORX's P/E ratio is -1.17. In terms of profitability, ZCMD's ROE is -0.32%, compared to WORX's ROE of -0.65%. Regarding short-term risk, ZCMD is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check WORX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, ZCMD is priced at $1.12, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas KERNW's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, ZCMD is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check KERNW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, ZCMD is priced at $1.12, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas KERN's P/E ratio is -0.01. In terms of profitability, ZCMD's ROE is -0.32%, compared to KERN's ROE of -0.17%. Regarding short-term risk, ZCMD is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check KERN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, ZCMD is priced at $1.12, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas LIFWW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, ZCMD is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check LIFWW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, ZCMD is priced at $1.12, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CMAXW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, ZCMD is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CMAXW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, ACONW has a market cap of 13.2K. Regarding current trading prices, ZCMD is priced at $1.12, while ACONW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas ACONW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, ZCMD is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check ACONW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas MSPRV's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MSPRV's ROE of N/A. Regarding short-term risk, ZCMD is less volatile compared to MSPRV. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MSPRV's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, NAVA has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas NAVA's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, Volatility data is not available for a full comparison. ZCMD has daily volatility of 17.19 and NAVA has daily volatility of N/A.Check NAVA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, AFFX has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas AFFX's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, ZCMD is more volatile compared to AFFX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AFFX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CHNGU's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, ZCMD is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CHNGU's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas MTBCP's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to MTBCP. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check MTBCP's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, MTBC has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas MTBC's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to MTBC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check MTBC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CHNG has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CHNG's P/E ratio is -152.72. In terms of profitability, ZCMD's ROE is -0.32%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, ZCMD is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CHNG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 38.9K. In comparison, CNVY has a market cap of 0. Regarding current trading prices, ZCMD is priced at $1.12, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.04, whereas CNVY's P/E ratio is -71.50. In terms of profitability, ZCMD's ROE is -0.32%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, ZCMD is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CNVY's competition here